Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT.

Ketterl TG, Flesher M, Shanley R, Miller W.

Bone Marrow Transplant. 2014 Apr;49(4):572-5. doi: 10.1038/bmt.2013.207. Epub 2014 Jan 13.

PMID:
24419524
2.

Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.

Rupa-Matysek J, Lewandowski K, Nowak W, Sawiński K, Gil L, Komarnicki M.

Transplant Proc. 2011 Jun;43(5):1915-23. doi: 10.1016/j.transproceed.2011.02.011.

PMID:
21693300
3.

Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis.

Willasch A, Eing S, Weber G, Kuçi S, Schneider G, Soerensen J, Jarisch A, Rettinger E, Koehl U, Klingebiel T, Kreyenberg H, Bader P.

Bone Marrow Transplant. 2010 Jan;45(1):181-9. doi: 10.1038/bmt.2009.89. Epub 2009 May 4.

PMID:
19421174
4.

Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.

El-Cheikh J, Vazquez A, Crocchiolo R, Furst S, Calmels B, Castagna L, Lemarie C, Granata A, Ladaique P, Oudin C, Faucher C, Chabannon C, Blaise D.

Am J Hematol. 2012 Dec;87(12):1074-8. doi: 10.1002/ajh.23319. Epub 2012 Aug 22.

5.

Early CD3 peripheral blood chimerism predicts the long-term engrafting unit following myeloablative double-cord blood transplantation.

Newell LF, Milano F, Nicoud IB, Pereira S, Gooley TA, Heimfeld S, Delaney C.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1243-9. doi: 10.1016/j.bbmt.2012.01.014. Epub 2012 Feb 8.

6.

[Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation].

Jiang Y, Wan LP, Wang C, Yan SK, Gao YR, Jiang JL, Yang J, Cai Y, Bai HT, Wei DL, Xie KC.

Zhonghua Xue Ye Xue Za Zhi. 2008 Oct;29(10):667-71. Chinese.

PMID:
19176059
7.

Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.

Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, Pawłowski R, Hellmann A.

Bone Marrow Transplant. 2005 Jun;35(11):1083-8.

PMID:
15821766
8.

Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.

Jiang Y, Wan L, Qin Y, Wang X, Yan S, Xie K, Wang C.

PLoS One. 2015 Jul 30;10(7):e0133671. doi: 10.1371/journal.pone.0133671. eCollection 2015.

9.

Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.

van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS.

Leuk Lymphoma. 2009 Nov;50(11):1809-17. doi: 10.3109/10428190903200790.

PMID:
19821799
10.

Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients.

Stikvoort A, Gertow J, Sundin M, Remberger M, Mattsson J, Uhlin M.

Biol Blood Marrow Transplant. 2013 May;19(5):838-44. doi: 10.1016/j.bbmt.2013.02.015. Epub 2013 Feb 24.

11.

[An analysis of leukocyte subsets chimerism following allogeneic peripheral blood stem cell transplantation].

Wan LP, Wang C, Yan SK, Li DQ, Qin YW, Xie KC.

Zhonghua Nei Ke Za Zhi. 2006 Jun;45(6):485-8. Chinese.

PMID:
16831328
12.

Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.

Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R, Pennings A, Boezeman J, Geurts van Kessel A, de Pauw B, de Witte T.

Leukemia. 2002 Jan;16(1):13-21.

13.
14.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
15.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10.

16.

Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.

Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN.

Bone Marrow Transplant. 2008 Jul;42(2):83-91. doi: 10.1038/bmt.2008.89. Epub 2008 Apr 7.

PMID:
18391990
17.

Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S, Gadner H, Lion T, Muller-Bérat N.

Leukemia. 1999 Dec;13(12):2059, 2060-9.

PMID:
10602430
18.

[Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].

Tang XW, Wu DP, Zhu ZL, Wang W, Sun AN, Qiu HY, Fu ZZ, Chang WR, Ruan CG.

Zhonghua Xue Ye Xue Za Zhi. 2004 Feb;25(2):78-81. Chinese.

PMID:
14990044
20.

Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

Doney K, Loken M, Bryant E, Smith A, Appelbaum F.

Bone Marrow Transplant. 2008 Aug;42(4):271-4. doi: 10.1038/bmt.2008.155. Epub 2008 May 26.

Supplemental Content

Support Center